title: Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors.
abstract: The structural complexity of chromosome 1p centromeric region has been an obstacle for fine mapping of tumor suppressor genes in this area. Loss of heterozygosity (LOH) on chromosome 1p is associated with the longer survival of oligodendroglioma (OD) patients. To test the clinical relevance of 1p loss in glioblastomas (GBM) patients and identifiy the underlying tumor suppressor locus, we constructed a somatic deletion map on chromosome 1p in 26 OG and 118 GBM. Deletion hotspots at 4 microsatellite markers located at 1p36.3, 1p36.1, 1p22 and 1p11 defined 10 distinct haplotypes that were related to patient survival. We found that loss of 1p centromeric marker D1S2696 within NOTCH2 intron 12 was associated with favorable prognosis in OD (P = 0.0007) as well as in GBM (P = 0.0175), while 19q loss, concomitant with 1p LOH in OD, had no influence on GBM survival (P = 0.918). Assessment of the intra-chromosomal ratio between NOTCH2 and its 1q21 pericentric duplication N2N (N2/N2N-test) allowed delineation of a consistent centromeric breakpoint in OD that also contained a minimally lost area in GBM. OD and GBM showed distinct deletion patterns that converged to the NOTCH2 gene in both glioma subtypes. Moreover, the N2/N2N-test disclosed homozygous deletions of NOTCH2 in primary OD. The N2/N2N test distinguished OD from GBM with a specificity of 100% and a sensitivity of 97%. Combined assessment of NOTCH2 genetic markers D1S2696 and N2/N2N predicted 24-month survival with an accuracy (0.925) that is equivalent to histological classification combined with the D1S2696 status (0.954) and higher than current genetic evaluation by 1p/19q LOH (0.762). Our data propose NOTCH2 as a powerful new molecular test to detect prognostically favorable gliomas.
authors.affiliation: Laboratory of Molecular Neuro-Oncology, Department of Research, University Hospital, Basel, Switzerland.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Boulay
authors.forename: André R
authors.initials: AR
authors.lastname: Miserez
authors.forename: Christian
authors.initials: C
authors.lastname: Zweifel
authors.forename: Balasubramanian
authors.initials: B
authors.lastname: Sivasankaran
authors.forename: Veronika
authors.initials: V
authors.lastname: Kana
authors.forename: Anthony
authors.initials: A
authors.lastname: Ghaffari
authors.forename: Cordelia
authors.initials: C
authors.lastname: Luyken
authors.forename: Michael
authors.initials: M
authors.lastname: Sabel
authors.forename: Abdessamad
authors.initials: A
authors.lastname: Zerrouqi
authors.forename: Morten
authors.initials: M
authors.lastname: Wasner
authors.forename: Erwin
authors.initials: E
authors.lastname: Van Meir
authors.forename: Markus
authors.initials: M
authors.lastname: Tolnay
authors.forename: Guido
authors.initials: G
authors.lastname: Reifenberger
authors.forename: Adrian
authors.initials: A
authors.lastname: Merlo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics*; D005260:Female; D016147:Genes, Tumor Suppressor; D005910:Glioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D018895:Microsatellite Repeats; D008875:Middle Aged; D051883:Receptor, Notch2 / Q000235:genetics*; D015996:Survival Rate; D055815:Young Adult
chemical_list: C497764:NOTCH2 protein, human; D051883:Receptor, Notch2